In an attempt to expand its interventional cardiology products portfolio, Medtronic plc recently revealed preclinical outcomes of its latest, groundbreaking Drug-Filled Stent (DFS), demonstrating the device’s safety and efficiency, at the 64 th Annual Scientific Session of the American College of Cardiology (ACC).
Following the news release, shares of this medical technology giant have risen 1.5% to eventually close at $77.61 yesterday.
Help employers find you! Check out all the jobs and post your resume.
